Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (MYGN) and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.

New discoveries are showing how genetic variations can affect our health, from disease risks to how we respond to medicines. Understanding the genetics of animals, plants, and microbes helps us see ...

LIMA, Peru, Dec. 1, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with the ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed ...

Founded in 2021, T3 Molecular Genetics Pvt Ltd. (T-3MGen) operates in the Health Tech sector offering new therapeutic interventions through multi-disciplinary ...

The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, ...

A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this ...

What we choose to study—whether fine art or finance—is one of the most influential decisions in our lives. It shapes not only ...

Genetically engineered breeders that lay only female chicks would eliminate the culling of day-old male chicks.